NHWD-870 is under clinical development by Ningbo Wenda Pharmaceutical Technology and currently in Phase II for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma). According to GlobalData, Phase II drugs for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NHWD-870 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NHWD-870 overview
NHWD-870 is under development for the treatment of diffuse large B-cell lymphoma and midline (NUT) cancer. The drug candidate acts by targeting bromodomain-containing proteins (BRD2, 3, 4, T).
The drug candidate was under development for the treatment of triple negative breast cancer, solid tumor or lymphomas including relapsed/refractory non-Hodgkins lymphoma, small-cell lung cancer, follicular lymphoma, non-small cell lung cancer, small-cell lung cancer, ovarian cancer and melanoma.
Ningbo Wenda Pharmaceutical Technology overview
Ningbo Wenda Pharmaceutical Technology (Ningbo Wenda Pharma) is a production of high-end drug intermediates and the development of innovative first-class new drugs. Ningbo Wenda Pharma is headquartered in Ningbo, Zhejiang, China.
For a complete picture of NHWD-870’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
